Key Drivers
- Robust cash generation
- Higher debt load
- Weaker liquidity
AIAI Summary
CHE is now principally a VITAS-driven healthcare growth story: strong census, margin expansion, and reduced Medicare-cap risk can support earnings, but investors should remain cautious until Roto-Rooter proves its Google-driven customer-acquisition costs are temporary rather than a structural margin reset—especially at an elevated valuation and with weaker liquidity.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Robust cash generation
- •Higher debt load
- •Weaker liquidity
CHE remains highly profitable with strong cash flow and interest coverage, but rising leverage, weakening liquidity, and richer valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Critical support
- •Weak momentum
CHE remains in a short-term downtrend, with $500–505 support critical; a break below $500 risks $490–492, while a move above $514–520 would ease bearish pressure.
Decline accelerated after the $549 peak
Sentiment & News
Key News Insights:
- •Institutional Accumulation
- •Roto-Rooter Expansion
- •Legal Scrutiny
Institutional buying and Roto-Rooter's $60.6M acquisition support Chemed's growth outlook, though insider selling and fiduciary-duty scrutiny present risks.
Overall sentiment is cautiously positive, with acquisition-led growth offset by governance-related uncertainty
Similar Companies in Healthcare
Other companies in the same sector with AI ratings